Enigma Genetics Pitch Deck
Published: November 11, 2025
1. Overview
Enigma Genetics™ is the world's first self-sovereign genetic identity and restoration platform. It empowers individuals to own, audit, and optimize their own genomic and epigenetic data over time. Our mission is to put people in full control of their biological information – from birth through aging – by providing portable biological IDs, encrypted personal vaults, and consent-driven data exchange.
This is a category-defining approach: unlike today's passive DNA data holders, Enigma positions users as active custodians of their biology. We are pre-seed (no prior raises) and Draper Associates is our first formal outreach. In short, we offer a novel DNA "passport" and wellness co-pilot that no other company currently provides.
2. The Problem
Fragmented Data & Centralized Silos
Today, genomic data are locked in proprietary silos (DTC databases, hospital EHRs, research repos) that limit accessibility and hinder research. In practice this means your genome and health history can't easily follow you to new doctors, and researchers struggle to aggregate data across sources.
No User Consent/Audit
Individuals have little real control over their DNA once it's out of the lab. Most sharing is governed by opaque terms; there is no built-in audit trail or revocation. This gap means you cannot easily see who has used your genome or revoke permissions – every data download is "invisible" to you.
Data Exploitation & Privacy Risks
There is a growing recognition that personal genomic data is extremely sensitive and at risk of exploitation. In recent news, a bankrupt 23andMe sold the data of ~15 million customers, illustrating how consumers lost control of their intimate profiles. Genetic information is effectively immutable (you can't change your genome), so once it's out, any leak or sale is permanent.
Untracked Epigenetic Drift
Beyond DNA sequence, a person's epigenome (methylation, chromatin state) changes with age, environment, stress and disease. These "epigenetic drifts" can impact health and aging, yet no consumer product tracks them systematically. Scientists have shown that loss of epigenetic information is a key driver of aging, and restoring epigenetic integrity can reverse aging signs in model organisms.
3. The Solution
Imagine a living QR code for your genome: that is Enigma's Cypherglyph™, a compact optical token encoding your genetic identity. Each Cypherglyph carries your unique DNA markers and tracks your epigenetic deltas over time (three concentric rings for static genome, dynamic methylation changes, plus metadata).
🔐 GeneVault™
A personal encrypted cloud vault for ALL your molecular data (raw FASTQ/BAM, VCFs, methylation arrays, etc). Access to GeneVault is always gated by user consent and multi-layer encryption (AES-256 plus lattice-based post-quantum keys).
👆 Unifacator™
Biometric Consent Gateway - Every data release or Cypherglyph scan requires live authentication by the data owner. The user provides a biometric signature (fingerprint, face ID, etc.), and Unifacator issues a signed consent token that unlocks exactly the approved data.
⛓️ SignaChain™
Blockchain Audit Ledger - All events (token scans, consent grants, data access, even CRISPR edit logs) are immutably recorded. SignaChain is a purpose-built blockchain ledger for biology that time-stamps and anchors every transaction.
🤖 OmniMind™
AI Analytics Engine - An intelligent engine that ingests your gene, epigenetic, and health data to provide actionable insights. OmniMind learns your "baseline" and continuously tracks drift vectors, predicting health risks and simulating epigenetic reversion.
4. Product/Service Offering
Enigma is delivered as a modular platform with clear user workflows. Each product is simple in concept but powerful in effect:
Use Case: Emergency Medical ID
You're unconscious; paramedics scan your Cypherglyph. They immediately see your blood type/allergies (vital keyblock) and, upon a quick biometric tap from their certified device, unlock a more detailed decryption of your conditions (all logged to SignaChain). You survive, and later you or your doctor review the consent log.
Use Case: Research & Monetization
A university needs DNA data for Alzheimer's studies. You approve a limited query on your genome (via Unifacator), the AI-only query runs in zero-knowledge, and your consent plus result (or a token payment) is recorded on SignaChain. You get compensation (via smart contract) for your contribution with full auditability.
Use Case: Personal Health/Wellness
You update your methylation profile yearly and scan your Cypherglyph at home. OmniMind notes a worrying drift in a longevity gene, alerts you, and suggests diet/supplements or a custom CRISPR therapeutic in the future.
5. Technology
Our stack is built on novel encoding, crypto, and AI technologies (patent-pending). Key highlights:
- •Non-standard Optical Token: The Cypherglyph format uses concentric data rings with custom fiducials to encode base-call nibbles and methylation deltas, designed for robustness and privacy.
- •Biometric Consent (Unifacator): Multi-factor biometric engine with secure enclaves – biometric templates stored only on-device.
- •Blockchain Audit (SignaChain): Permissioned blockchain with zero-knowledge proof techniques for data queries, making events tamper-evident and auditable.
- •Post-Quantum Readiness: Layered AES-256 with lattice-based schemes to resist future quantum attacks.
- •AI/ML Analytics (OmniMind): Cloud-based with federated learning and differential privacy, incorporating epigenetic aging clocks to estimate biological age.
6. Revenue Model
Enigma's business model aligns incentives across consumers, developers, and institutions:
💳 Subscription Vaults
Tiered plans for GeneVault storage and token updates with 80-90% margins
🔌 SDK/API Licensing
Enterprise licensing for health systems and research networks
💰 Data Royalty Marketplace
80% of research fees distributed to users, Enigma takes a cut
🏢 B2B Integrations
White-label solutions and partnerships with clinics and governments
| Metric | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Users (vault subscribers) | 10,000 | 30,000 | 50,000 |
| Monthly ARPU | $20 | $25 | $30 |
| ARR (vault) | $2.4M | $9.0M | $18.0M |
| API/SDK sales | $0.5M | $1.5M | $3.0M |
| Marketplace revenue | $0.2M | $0.8M | $2.0M |
| Total ARR | $3.1M | $11.3M | $23.0M |
| Gross Margin | ~60% | ~65% | ~70% |
7. Customer Benefits
Enigma is designed to "delight" by putting users back in the driver's seat:
- •Privacy-By-Design: All data is encrypted and stored for you only. No hidden terms mean no surprise data sales.
- •Visual Feedback (Cypherglyph): Users get a clear, intuitive representation of their genome that changes visibly as methylation changes.
- •Emergency Access with Audit: First responders get what they need instantly, yet you control exactly what is seen and all access is logged.
- •Optional Monetization: Users can opt into research and get paid for queries on their data under their own terms.
8. Viral/Network Effects
Enigma's platform fosters organic growth through network effects:
- •Research Opt-In Network: Every new user increases data pool diversity, attracting more studies and creating a virtuous cycle.
- •Biometric Consent Marketplace: As more apps integrate Unifacator, it becomes the de facto standard "proof-of-humanity."
- •Verifiable Humanity & Reputation: Blockchain logging powers reputation systems that encourage trust and participation.
- •Generative Bio-Art (NFTs): Users create and share personalized genome art on social media, providing viral word-of-mouth growth.
9. Fundraising Dynamics
We are raising a $2.5M seed round to deploy the MVP and hit key milestones. There have been no prior outside raises; the founder has bootstrapped development to date. The cap table is clean with no external investors or option pools beyond early co-founders.
Use of Funds:
- •~40% for product development (MVP, Cypherglyph prototypes, GeneVault deployment)
- •~20% for compliance, security audits, and certifications (GDPR, HIPAA readiness, IRB partnerships)
- •~20% for launching a CRISPR-epigenetics pilot (research lab collaboration for epigenetic interventions)
- •~10% for marketing/BD (partnerships with genomics labs and healthcare providers)
- •~10% for team hire (security engineer and regulatory affairs specialist)
10. Team
Kenneth J. Clark – Founder & CEO
A visionary engineer and inventor with deep domain expertise. Ken has a strong background in operations and automation from his tenure at Tesla (where he led patented work on robotic manufacturing systems). Ken is also a published author on biometric security and is the named inventor on the core Enigma patents (covering Cypherglyph, Unifacator, etc.). He single-handedly built the MVP architecture, designed the key encoding schemes, and conducted the market analysis and financial modeling. As a full-stack technologist, Ken bridges lab science and code with hands-on experience in genome sequencing, bioinformatics, blockchain development, and AI.
References & Sources
[1] [11] Blockchain-Enabled Privacy-Preserving Ecosystem for DNA Sequence Sharing
[2] [3] [9] [10] [13] A Blockchain-Based Dynamic Consent Architecture to Support Clinical Genomic Data Sharing (ConsentChain)
[4] [6] [12] EPIC – Electronic Privacy Information Center: 23andMe Privacy and Data Security Analysis
[5] Center for Genetics and Society: The Precarious Future of Consumer Genetic Privacy
[7] Harvard Medical School: Loss of Epigenetic Information Can Drive Aging, Restoration Can Reverse It
[8] IEEE Paper: Privacy-Preserving Genomic Analysis Using Zero-Knowledge Proofs